Trials / Not Yet Recruiting
Not Yet RecruitingNCT07454031
Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
An Investigator-Initiated Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intraperitoneal PX in combination with nab-paclitaxel | intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, |
Timeline
- Start date
- 2026-03-15
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2026-03-06
- Last updated
- 2026-03-13
Source: ClinicalTrials.gov record NCT07454031. Inclusion in this directory is not an endorsement.